Email this article Invasive potential of retroperitoneal well-differentiated liposarcomas depending on the extent of sclerosing component in the tumor
- Authors: Volkov A.Y.1, Kozlov N.A.1, Nered S.N.1, Stilidi I.S.1, Stroganova A.M.1, Archery P.P.1, Antonov E.Y.1, Privezentsev S.A.2
-
Affiliations:
- N.N. Blokhin National Medical Research Center of Oncology
- D.D. Pletnev City Clinical Hospital
- Issue: Vol 25, No 2 (2020)
- Pages: 50-55
- Section: Original Study Articles
- URL: https://rjonco.com/1028-9984/article/view/43677
- DOI: https://doi.org/10.17816/1028-9984-2020-25-2-50-55
- ID: 43677
Cite item
Open Access
Access granted
Abstract
Objective. To assess the influence of the extent of sclerosing component in the retroperitoneal well-differentiated liposarcoma (WDLPS) on the survival.
Material and methods. The retrospective study included 111 patients with primary retroperitoneal WLPS who underwent radical surgical treatment in Federal State Budgetary Institution «N.N. Blokhin National Medical Research Center of Oncology». Histological slides of all surgical specimens were reviewed by experienced pathologist and reclassified according to criteria of WHO (2013). Patients were divided into groups depending on the extent of the sclerosing component in the tumor and enrolled in intergroup analysis. We analyzed relationship between extent of the sclerosing component in the tumor and frequency of the pathologically confirmed visceral invasion. Also, we have analyzed the influence of the visceral invasion of WDLPS on the long-term results – overall (OS) and recurrence-free (RFS) survival.
Results. Pathologically confirmed visceral invasion was revealed in 17% of cases with the sclerosing component less 20%, and in 31% of cases with the sclerosing component more 20%. OS was significantly worse in the group of patients who suffered from WDLPS with visceral invasion than in the group of patients without visceral invasion (p = 0.009; logarithmic criterion). The median OS in the compared groups was 85 (95% CI, 84, 87) and 142 (95% CI, 109, 175) months, the 5-year OS rate was 41% and 86%, respectively. RFS was significantly worse in the group of patients with histologically confirmed visceral invasion than in the group without organ invasion (p = 0.001; logarithmic criterion). Median RFS in the compared groups was 26 (95% CI, 20, 32) and 57 (95% CI, 38, 76) months, 2-year RFS 33% and 85%, respectively.
Conclusion. Results of the study demonstrate more aggressive behavior of WDLPS with increasing extent of the sclerosing component. We believe that semi-quantitative counting of sclerosing component in retroperitoneal WDLPS can serve as an effective morphological marker of a less favorable prognosis of the disease.
Full Text
About the authors
A. Yu. Volkov
N.N. Blokhin National Medical Research Center of Oncology
Author for correspondence.
Email: 79164577128@yandex.ru
ORCID iD: 0000-0003-4412-2256
MD, PhD student, the oncological department of surgical methods of treatment №6 (abdominal oncology). N. N. Blokhin National Medical Research Centre of oncology
Russian Federation, MoscowN. A. Kozlov
N.N. Blokhin National Medical Research Center of Oncology
Email: 79164577128@yandex.ru
Russian Federation, Moscow
S. N. Nered
N.N. Blokhin National Medical Research Center of Oncology
Email: 79164577128@yandex.ru
Russian Federation, Moscow
I. S. Stilidi
N.N. Blokhin National Medical Research Center of Oncology
Email: 79164577128@yandex.ru
Russian Federation, Moscow
A. M. Stroganova
N.N. Blokhin National Medical Research Center of Oncology
Email: 79164577128@yandex.ru
Russian Federation, Moscow
P. P. Archery
N.N. Blokhin National Medical Research Center of Oncology
Email: 79164577128@yandex.ru
Russian Federation, Moscow
E. Yu. Antonov
N.N. Blokhin National Medical Research Center of Oncology
Email: 79164577128@yandex.ru
Russian Federation, Moscow
S. A. Privezentsev
D.D. Pletnev City Clinical Hospital
Email: 79164577128@yandex.ru
Russian Federation, Moscow
References
- Raut C.P., Miceli R., Strauss D.C., Swallow C.J. et al. External validation of a multi-institutional retroperitoneal sarcoma nomogram. Cancer. 2016; 1; 122 (9): 1417–24. doi: 10.1002/cncr.29931.
- Smith C.A., Martinez S.R., Tseng W.H., Tamurian R.M., Bold R.J., Borys D., Canter R.J. Predicting survival for well-differentiated liposarcoma: the importance of tumor location. J. Surg. Res. 2012; 1;175 (1): 12–7. doi: 10.1016/j.jss.2011.07.024.
- Fletcher C.D., Bridge J.A., Hogendoorn P., Mertens F. WHO Classification of Tumours of soft tissue and bone. 4th Ed. IARC. 2013; 33–44
- Canter R.J., Qin L.X., Ferrone C.R., Maki R.G., Singer S., Brennan M.F. Why do patients with low-grade soft tissue sarcoma die? Ann. Surg. Oncol. 2008; 15 (12): 3550–60. doi: 10.1245/s10434-008-0163-0.
- Matthyssens L.E., Creytens D., Ceelen W.P. Retroperitoneal liposarcoma: current insights in diagnosis and treatment. Front. Surg. 2015; 10; 2: 4. doi: 10.3389/fsurg.2015.00004. PMID: 25713799; PMCID: PMC4322543.
- Raut C.P., Miceli R., Strauss D.C., Swallow C.J. et al. External validation of a multi-institutional retroperitoneal sarcoma nomogram. Cancer. 2016; 122 (9): 1417–24. doi: 10.1002/cncr.29931.
- Nered S.N., Stilidi I.S., Klimenkov A.A., Bolotskiy V.I., Anuro-va O.A. Clinical and morphological features and results of surgical treatment of retroperitoneal non-organ liposarcomas. Voprosy onkologii. 2012; 58 (1): 94–100. (in Russian)
- Liles J.S., Tzeng C.W.D., Short J.J., Kulesza P., Heslin M.J. Retroperitoneal and intra-abdominal sarcoma. Curr. Probl. Surg. 2009; 46 (6): 445–503. doi: 10.1067/j.cpsurg.2009.01.004
- Bonvalot S., Rivoire M., Castaing M., Stoeckle E., Le Cesne A., Blay J.Y., Laplanche A. Primary retroperitoneal sarcomas: a multivariate analysis of surgical factors associated with local control. J. Clin. Oncol. 2009; 1; 27 (1): 31–7. doi: 10.1200/JCO.2008.18.0802.
- Strauss D.C., Hayes A.J., Thway K., Moskovic E.C., Fisher C., Thomas J.M. Surgical management of primary retroperitoneal sarcoma. Br. J. Surg. 2010; 97 (5): 698–706. doi: 10.1002/bjs.6994.
- Thway K., Flora R., Shah C., Olmos D., Fisher C. Diagnostic utility of p16, CDK4, and MDM2 as an immunohistochemical panel in distinguishing well-differentiated and dedifferentiated liposarcomas from other adipocytic tumors. Am. J. Surg. Pathol. 2012; 36 (3): 462–9.
- Italiano A., Bianchini L., Keslair F., Bonnafous S. et al. HMGA2 is the partner of MDM2 in well-differentiated and dedifferentiated liposarcomas whereas CDK4 belongs to a distinct inconsistent amplicon. Int. J. Cancer. 2008; 122 (10): 2233–41.
- Sirvent N., Coindre J.M., Maire G., Hostein I., Keslair F., Guillou L., Ranchere-Vince D., Terrier P., Pedeutour F. Detection of MDM2-CDK4 amplification by fluorescence in situ hybridization in 200 paraffin-embedded tumor samples: utility in diagnosing adipocytic lesions and comparison with immunohistochemistry and real-time PCR. Am. J. Surg. Pathol. 2007; 31 (10): 1476–89. doi: 10.1097/PAS.0b013e3180581fff.
- Chrisinger J.S.A., Al-Zaid T., Keung E.Z., Leung C., Lin H.Y., Roland C.L., Torres K.E., Benjamin R.S., Ingram D.R., Khan S., Somaiah N., Amini B., Feig B.W., Lazar A.J., Wang W.L. The degree of sclerosis is associated with prognosis in well-differentiated liposarcoma of the retroperitoneum. J. Surg. Oncol. 2019; 120 (3): 382–88.
- Volkov A.Yu., Kozlov N.A., Nered S.N., Stilidi I,S,, Stroganova A.M., Archery P.P., Antonov E.Yu., Privezentsev S.A. Retroperitoneal well-differentiated liposarcoma: prognostic significance of the degree of sclerosis in the tumor. Sarkomy kostey myagkih tkaney i opukhali kozhi. 2020; 12 (1): 14–23. (in Russian)
Supplementary files
